2023年3月15日

VCPro数据库2023 26日版-一个可下载的和可搜索的数据库与风险资本6900 +全球风险资本和私人股本公司。最可靠的、最新的和负担得起的风险资本的目录。VCPro数据库可以在Windows和macOS版本。自1998年以来,它已经出版。开关疗法启动5200万美元推进首开先河的RNAi技术——基因的新方法可拆卸的使用专利属于接近(有条件地激活核分子优化“开关”,激活核疗法只在选定的细胞——属于接近平台,基于技术发达的加州理工学院,哈佛大学和城市的希望,拥有广泛的治疗潜能;最初的努力集中在中枢神经系统——南旧金山,加利福尼亚州,3月14日,2023年,开关疗法,临床前阶段生物科技公司开拓一种新的方式使用RNA科学治疗疾病,今天宣布推出5200万美元的融资。公司的系列被了解合作伙伴和共同的联合企业,在现有投资者额外的资金,包括前期项目和大胆Capital Partners和新投资者礼来公司,小野风险投资,洋地黄,杜比家庭企业,企业自由流动,PhiFund企业等等。”这是一个转型的时代RNA药物和我们兴奋地应用科学发现的方式可能会导致新的治疗突破,有可能治疗一些最具破坏性的疾病,”迪达塔说,博士,开关疗法的联合创始人兼首席执行官。“我们的方法使用小说属于接近分子独特self-deliver高效,高强度和长时间的效果。此外,我们可以设计属于接近分子只在选择细胞激活,允许扩张目标,可能需要精密RNAi方法。 We are grateful for the support of our investors and are eager to continue advancing our research to build a world-class pipeline of new molecules.” The funds raised will be used to select and advance a development candidate for Switch’s lead program for the treatment of a central nervous system disease and recruit top R&D and corporate talent to help accelerate the company’s growth. The company also intends to explore opportunities to expand its CASi platform into new areas through potential pharmaceutical collaborations. Switch was founded on the premise of a new type of RNA medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science. Based on the scientific discovery of its co-founders, including Chief Technology Officer Si-ping Han, Ph.D., Switch’s proprietary CASi platform combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity, as well as efficient self-delivery and uptake, potency and duration of knockdown. CASi molecules use a small interfering RNA (siRNA) structure with structural extensions to allow for docking to a sensor developed by Switch. The sensor allows efficient delivery of the siRNA while regulating the siRNA’s activity to “switch on” only in selected cells. “With CASi, Switch has developed a cell-selective gene knockdown platform that could pave the way for the next generation of RNAi therapies,” said Dylan Morris, Managing Director of Insight Partners, a co-lead investor. “We seek out the most promising early-stage companies that combine experienced leaders with unique technologies, and we’re excited to work with the team at Switch as they advance their efforts forward.” “With its pioneering science that could have broad therapeutic applications, Switch is at the forefront of evolving what’s possible with RNA-based approaches to medicine,” said Alicia Irurzun-Lafitte, Partner of UCB Ventures, a co-lead investor. “UCB Ventures is passionate about funding innovative companies and we are pleased to support Switch as it works to realize the potential of the CASi platform and its future impact for patients.” About Switch Therapeutics Switch Therapeutics is an emerging biotechnology company pioneering a new type of medicine that integrates nucleic acid nanotechnology and RNA interference (RNAi) science, with the goal of treating a range of diseases - affecting the central nervous system and systemic indications – with significant unmet need. The CASi (Conditionally Activated siRNA) platform, the company’s novel gene knockdown approach, is based on technology developed by renowned researchers in the field of RNA and drug development from Caltech, Harvard Medical School and City of Hope. CASi combines advantageous properties of both single and double-stranded RNAs in a single molecule, allowing for cell selective RNAi activity. Switch is based in South San Francisco, California. For more information, connect with Switch on LinkedIn or visit www.switchthera.com Contact: